Research on the clinical application of psychedelics is gaining momentum. However major knowledge gaps remain regarding the mechanisms of action underlying beneficial therapeutic effects of these substances. Understanding the clinical mechanisms of action will help to inform, optimize, and advance currently implemented psychotherapeutic approaches in the context of psychedelic-assisted therapy. Testing these approaches empirically is essential to be able to provide evidence-based psychedelic-assisted therapy and maximize the clinical potential of psychedelic substances in the treatment of psychiatric disorders. In this talk, I will present current insights into the mechanisms of action of psychedelics. Furthermore, I will discuss the implications these insights have for the conduction of psychedelic-assisted therapy and suggest potential synergistic effects between pharmacological mechanisms and non-pharmacological treatment approaches
The benefits of psychedelic therapy have been very well documented over the past number of years, with cutting edge scientific research showing the healing potential of substances like psilocybin.<
Psilocybin‐assisted therapy shows clear potential for depression and other indications in recent clinical trials. While there are two FDA Breakthrough designation programmes with psilocybin for d
Psychedelic ingestion and meditative practice are both ancient methods for altering consciousness that became widely known in Western society in the second half of the 20th<
Current clinical trials with psychedelics mostly use psilocybin. However, there are other classic psychedelics such as LSD, DMT and mescaline that may be useful. The presentation will give an overv
© MIND Foundation 2023
Proud to be part of the MIND Foundation
